NetworkNewsBreaks – Oncotelic Therapeutics, Inc.
Post# of 69
(Total Views: 57)
Posted On: 10/28/2025 5:10:26 PM
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Innovations in Oncology
Oncotelic Therapeutics (OTCQB: OTLC) today announced its inclusion in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a communications platform specializing in financial news and content distribution. The article, titled “Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology,” highlights how nanocarrier-based delivery systems are transforming cancer treatment. Oncotelic’s Deciparticle(TM) platform exemplifies this progress by improving bioavailability and therapeutic index across multiple oncology drugs. The advancement of Sapu-003, Intravenous Deciparticle(TM) Everolimus (Afinitor(R)), into human trials underscores the company’s innovation in drug delivery and its mission to enhance efficacy and patient outcomes.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Oncotelic Therapeutics (OTCQB: OTLC) today announced its inclusion in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a communications platform specializing in financial news and content distribution. The article, titled “Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology,” highlights how nanocarrier-based delivery systems are transforming cancer treatment. Oncotelic’s Deciparticle(TM) platform exemplifies this progress by improving bioavailability and therapeutic index across multiple oncology drugs. The advancement of Sapu-003, Intravenous Deciparticle(TM) Everolimus (Afinitor(R)), into human trials underscores the company’s innovation in drug delivery and its mission to enhance efficacy and patient outcomes.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)